Global Ai Solutions for Cardiovascular Diseases 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI06250085

Publication Date:

June 17, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

IT Services [2]

Software [3]

Computing & Electronics [4]

Description:

The global Ai Solutions for Cardiovascular Diseases market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
AI solutions for cardiovascular diseases refer to applications of artificial intelligence in the field of cardiology and heart-related healthcare. These solutions use machine learning algorithms and data analysis to assist in diagnosing, monitoring, and treating cardiovascular conditions, including heart disease, arrhythmias, and more.
China and the United States are two leaders in AI industry. On the AI 100 list (2022) released by CB Insights, the number of companies in the United States ranks first, with more than 70 companies, followed by the United Kingdom, with 8 companies on the list. China and Canada both holds 5 companies on the list. According to data from the China Academy of Information and Communications Technology, the scale of China"s core artificial intelligence industry reached 楼508 billion in 2022, a year-on-year increase of 18%. From 2013 to November 2022, the cumulative number of patent applications for artificial intelligence inventions in the world reached 729,000, and the cumulative number of applications in China reached 389,000, accounting for 53.4%. However, the Global Artificial Intelligence Innovation Index Report 2021 released by the China Institute of Scientific and Technological Information shows that the overall strength of the United States is still far ahead. The number of artificial intelligence companies in the United States is about 4,670, while China has only 880. China"s data center is less than 1/136 of that of the United States.
The 鈥淎i Solutions for Cardiovascular Diseases Industry Forecast鈥� looks at past sales and reviews total world Ai Solutions for Cardiovascular Diseases sales in 2024, providing a comprehensive analysis by region and market sector of projected Ai Solutions for Cardiovascular Diseases sales for 2025 through 2031. With Ai Solutions for Cardiovascular Diseases sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ai Solutions for Cardiovascular Diseases industry.
This Insight Report provides a comprehensive analysis of the global Ai Solutions for Cardiovascular Diseases landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Ai Solutions for Cardiovascular Diseases portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Ai Solutions for Cardiovascular Diseases market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ai Solutions for Cardiovascular Diseases and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ai Solutions for Cardiovascular Diseases.
This report presents a comprehensive overview, market shares, and growth opportunities of Ai Solutions for Cardiovascular Diseases market by product type, application, key players and key regions and countries.
Segmentation by Type:
Services
Software
Segmentation by Application:
Clinics
Nursing Center
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Idoven
Eko
Cardiologs
Viz.ai
AliveCor
Caption Health
Ultromics

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Ai Solutions for Cardiovascular Diseases 麻豆原创 Size (2020-2031)
2.1.2 Ai Solutions for Cardiovascular Diseases 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Ai Solutions for Cardiovascular Diseases by Country/Region (2020, 2024 & 2031)
2.2 Ai Solutions for Cardiovascular Diseases Segment by Type
2.2.1 Services
2.2.2 Software
2.3 Ai Solutions for Cardiovascular Diseases 麻豆原创 Size by Type
2.3.1 Ai Solutions for Cardiovascular Diseases 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Ai Solutions for Cardiovascular Diseases 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Ai Solutions for Cardiovascular Diseases Segment by Application
2.4.1 Clinics
2.4.2 Nursing Center
2.4.3 Others
2.5 Ai Solutions for Cardiovascular Diseases 麻豆原创 Size by Application
2.5.1 Ai Solutions for Cardiovascular Diseases 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Ai Solutions for Cardiovascular Diseases 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Ai Solutions for Cardiovascular Diseases 麻豆原创 Size by Player
3.1 Ai Solutions for Cardiovascular Diseases 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Ai Solutions for Cardiovascular Diseases Revenue by Player (2020-2025)
3.1.2 Global Ai Solutions for Cardiovascular Diseases Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Ai Solutions for Cardiovascular Diseases Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Ai Solutions for Cardiovascular Diseases by Region
4.1 Ai Solutions for Cardiovascular Diseases 麻豆原创 Size by Region (2020-2025)
4.2 Global Ai Solutions for Cardiovascular Diseases Annual Revenue by Country/Region (2020-2025)
4.3 Americas Ai Solutions for Cardiovascular Diseases 麻豆原创 Size Growth (2020-2025)
4.4 APAC Ai Solutions for Cardiovascular Diseases 麻豆原创 Size Growth (2020-2025)
4.5 Europe Ai Solutions for Cardiovascular Diseases 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Ai Solutions for Cardiovascular Diseases 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Ai Solutions for Cardiovascular Diseases 麻豆原创 Size by Country (2020-2025)
5.2 Americas Ai Solutions for Cardiovascular Diseases 麻豆原创 Size by Type (2020-2025)
5.3 Americas Ai Solutions for Cardiovascular Diseases 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Ai Solutions for Cardiovascular Diseases 麻豆原创 Size by Region (2020-2025)
6.2 APAC Ai Solutions for Cardiovascular Diseases 麻豆原创 Size by Type (2020-2025)
6.3 APAC Ai Solutions for Cardiovascular Diseases 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Ai Solutions for Cardiovascular Diseases 麻豆原创 Size by Country (2020-2025)
7.2 Europe Ai Solutions for Cardiovascular Diseases 麻豆原创 Size by Type (2020-2025)
7.3 Europe Ai Solutions for Cardiovascular Diseases 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Ai Solutions for Cardiovascular Diseases by Region (2020-2025)
8.2 Middle East & Africa Ai Solutions for Cardiovascular Diseases 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Ai Solutions for Cardiovascular Diseases 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Ai Solutions for Cardiovascular Diseases 麻豆原创 Forecast
10.1 Global Ai Solutions for Cardiovascular Diseases Forecast by Region (2026-2031)
10.1.1 Global Ai Solutions for Cardiovascular Diseases Forecast by Region (2026-2031)
10.1.2 Americas Ai Solutions for Cardiovascular Diseases Forecast
10.1.3 APAC Ai Solutions for Cardiovascular Diseases Forecast
10.1.4 Europe Ai Solutions for Cardiovascular Diseases Forecast
10.1.5 Middle East & Africa Ai Solutions for Cardiovascular Diseases Forecast
10.2 Americas Ai Solutions for Cardiovascular Diseases Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Ai Solutions for Cardiovascular Diseases Forecast
10.2.2 Canada 麻豆原创 Ai Solutions for Cardiovascular Diseases Forecast
10.2.3 Mexico 麻豆原创 Ai Solutions for Cardiovascular Diseases Forecast
10.2.4 Brazil 麻豆原创 Ai Solutions for Cardiovascular Diseases Forecast
10.3 APAC Ai Solutions for Cardiovascular Diseases Forecast by Region (2026-2031)
10.3.1 China Ai Solutions for Cardiovascular Diseases 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Ai Solutions for Cardiovascular Diseases Forecast
10.3.3 Korea 麻豆原创 Ai Solutions for Cardiovascular Diseases Forecast
10.3.4 Southeast Asia 麻豆原创 Ai Solutions for Cardiovascular Diseases Forecast
10.3.5 India 麻豆原创 Ai Solutions for Cardiovascular Diseases Forecast
10.3.6 Australia 麻豆原创 Ai Solutions for Cardiovascular Diseases Forecast
10.4 Europe Ai Solutions for Cardiovascular Diseases Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Ai Solutions for Cardiovascular Diseases Forecast
10.4.2 France 麻豆原创 Ai Solutions for Cardiovascular Diseases Forecast
10.4.3 UK 麻豆原创 Ai Solutions for Cardiovascular Diseases Forecast
10.4.4 Italy 麻豆原创 Ai Solutions for Cardiovascular Diseases Forecast
10.4.5 Russia 麻豆原创 Ai Solutions for Cardiovascular Diseases Forecast
10.5 Middle East & Africa Ai Solutions for Cardiovascular Diseases Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Ai Solutions for Cardiovascular Diseases Forecast
10.5.2 South Africa 麻豆原创 Ai Solutions for Cardiovascular Diseases Forecast
10.5.3 Israel 麻豆原创 Ai Solutions for Cardiovascular Diseases Forecast
10.5.4 Turkey 麻豆原创 Ai Solutions for Cardiovascular Diseases Forecast
10.6 Global Ai Solutions for Cardiovascular Diseases Forecast by Type (2026-2031)
10.7 Global Ai Solutions for Cardiovascular Diseases Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Ai Solutions for Cardiovascular Diseases Forecast
11 Key Players Analysis
11.1 Idoven
11.1.1 Idoven Company Information
11.1.2 Idoven Ai Solutions for Cardiovascular Diseases Product Offered
11.1.3 Idoven Ai Solutions for Cardiovascular Diseases Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Idoven Main Business Overview
11.1.5 Idoven Latest Developments
11.2 Eko
11.2.1 Eko Company Information
11.2.2 Eko Ai Solutions for Cardiovascular Diseases Product Offered
11.2.3 Eko Ai Solutions for Cardiovascular Diseases Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Eko Main Business Overview
11.2.5 Eko Latest Developments
11.3 Cardiologs
11.3.1 Cardiologs Company Information
11.3.2 Cardiologs Ai Solutions for Cardiovascular Diseases Product Offered
11.3.3 Cardiologs Ai Solutions for Cardiovascular Diseases Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Cardiologs Main Business Overview
11.3.5 Cardiologs Latest Developments
11.4 Viz.ai
11.4.1 Viz.ai Company Information
11.4.2 Viz.ai Ai Solutions for Cardiovascular Diseases Product Offered
11.4.3 Viz.ai Ai Solutions for Cardiovascular Diseases Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Viz.ai Main Business Overview
11.4.5 Viz.ai Latest Developments
11.5 AliveCor
11.5.1 AliveCor Company Information
11.5.2 AliveCor Ai Solutions for Cardiovascular Diseases Product Offered
11.5.3 AliveCor Ai Solutions for Cardiovascular Diseases Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 AliveCor Main Business Overview
11.5.5 AliveCor Latest Developments
11.6 Caption Health
11.6.1 Caption Health Company Information
11.6.2 Caption Health Ai Solutions for Cardiovascular Diseases Product Offered
11.6.3 Caption Health Ai Solutions for Cardiovascular Diseases Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Caption Health Main Business Overview
11.6.5 Caption Health Latest Developments
11.7 Ultromics
11.7.1 Ultromics Company Information
11.7.2 Ultromics Ai Solutions for Cardiovascular Diseases Product Offered
11.7.3 Ultromics Ai Solutions for Cardiovascular Diseases Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Ultromics Main Business Overview
11.7.5 Ultromics Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.